1. Home
  2. INFQ vs AGIO Comparison

INFQ vs AGIO Comparison

Compare INFQ & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

INFQ

Infleqtion Inc. Common Stock

N/A

Current Price

$10.57

Market Cap

2.3B

Sector

Technology

ML Signal

N/A

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$35.20

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INFQ
AGIO
Founded
2007
2007
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.0B
IPO Year
2026
2013

Fundamental Metrics

Financial Performance
Metric
INFQ
AGIO
Price
$10.57
$35.20
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$38.50
AVG Volume (30 Days)
2.5M
830.5K
Earning Date
N/A
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
N/A
$74.95
Revenue Next Year
N/A
$165.77
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.52
$22.24
52 Week High
$13.70
$46.00

Technical Indicators

Market Signals
Indicator
INFQ
AGIO
Relative Strength Index (RSI) 48.90 78.70
Support Level $10.32 $32.68
Resistance Level $12.16 $43.72
Average True Range (ATR) 0.94 1.34
MACD 0.05 0.73
Stochastic Oscillator 63.07 87.15

Price Performance

Historical Comparison
INFQ
AGIO

About INFQ Infleqtion Inc. Common Stock

Infleqtion Inc develops and commercializes neutral atom-based quantum technology products through an integrated platform. Its offerings include quantum sensing, quantum computing, and related software solutions. The company's technologies are deployed across sectors such as defense and security, artificial intelligence, energy optimization, space applications, materials research, and cybersecurity. Its platform integrates core quantum technologies with hardware and proprietary software based on neutral atom systems.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

Share on Social Networks: